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Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer 
immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains 
unclear. We examined HLA class I expression in 2 distinct tumor compartments, 
namely, the tumor center and invasive front, and evaluated the association between 
its expression pattern and histopathological status in 137 cases with OSCC. Human 
leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and 
negative. At the invasive front of the tumor, HLA class I expression was high in 72 
cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA 
class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases 
(42.4%), and negative in 31 cases (22.6%). The 5-year overall survival and disease-
specific survival rates were good in cases with high HLA class I expression at the 
invasive front; however, there was no significant difference in survival based on HLA 
class I expression in the tumor center. In addition, high HLA class I expression was 
correlated with high CD8+ T cell density, whereas negative HLA class I expression 
was correlated with low CD8+ T cell density at the invasive front. These results sug-
gest that it is easier for CD8+ T cells to recognize presented peptides in the case of 
high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic 
factor for OSCC.
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1  | INTRODUC TION
Oral cancer is the ninth most common malignancy worldwide,1 with 
OSCC representing approximately 90% of oral malignancies. Despite 
advanced knowledge of cancer therapy, more than 145 000 deaths 
from oral cancer occur annually,1 with a 5-year survival rate of ap-
proximately 50% for OSCC.2 Unfortunately, this rate has not im-
proved in recent decades, indicating a need for new treatments and 
therapeutic approaches.2
Cancer cells can evade immune surveillance, allowing them to 
grow and metastasize. One mechanism of immune escape during 
cancer development is the downregulation of the expression of HLA 
class I molecules,3-6 which are expressed on all nucleated cells and 
present intracellular protein fragments on the cell surface, partic-
ularly for recognition by CTLs, eg, CD8+ T cells.7 The status of the 
immune system is an important factor in the prognosis of cancer 
patients, and HLA class I antigen downregulation has been used 
as a prognostic biomarker in esophageal cancer,8 malignant mela-
noma,9 lung cancer,10 ovarian cancer,11 colon cancer,12 renal cell 
carcinoma,13 and bladder cancer,14 thus improving the survival of pa-
tients. However, the downregulation of HLA class I expression is not 
observed in all types of cancer, such as gastric cancer.15 Regardless, 
the loss of HLA class I molecules has been discussed in the context 
of tumor aggressiveness, including differentiation, invasiveness, and 
metastatic potential.16,17
Because most anti-HLA class I Abs recognize the allele-specific 
native structure of HLA class I molecules, these Abs are unable to 
react with denatured HLA class I molecules in formalin-fixed par-
affin-embedded tissue sections. However, a monoclonal pan-HLA 
class I Ab, EMR8-5, has been developed that is suitable for immu-
nostaining formalin-fixed tissue specimens.18 Therefore, we are now 
able to retrospectively investigate HLA class I expression in surgi-
cally resected cancer specimens.
We recently reported that tumor-infiltrating CD8⁺ T cell density 
was an independent prognostic marker for OSCC; specifically, CD8+ 
T cells at the parenchyma of the invasive edge of the tumor were 
an indicator of recurrence and prognosis.19 However, there are few 
reports on HLA class I expression in OSCC,20,21 and no study has 
examined the association between HLA class I expression and CD8+ 
T cell density in detail. Therefore, in this study, we focused on the 
expression of HLA class I molecules in cancer cells and its relation-
ship with CD8+ T cell density to investigate its prognostic value in 
patients with OSCC.
2  | MATERIAL S AND METHODS
2.1 | Patients and tissue samples
This retrospective study was undertaken according to the principles 
of the 1964 Declaration of Helsinki and its subsequent revisions and 
was approved by the Institutional Review Board of our university on 
12 September 2017 (No. 292-1116). Informed consent or acceptable 
substitutes were obtained from all patients before study inclusion. 
We used tissue samples collected from patients who were diagnosed 
with OSCC and underwent definitive surgery between January 
2004 and December 2014 at Sapporo Medical University Hospital 
(Table 1). Tissue samples were processed, embedded in paraffin, 
and sectioned into 4-μm samples. None of the patients received any 
form of neoadjuvant or adjuvant chemo- and/or radiotherapy before 
or after surgery.
2.2 | Immunohistochemistry
The monoclonal anti-pan-HLA class I Ab EMR8-5 was established by 
Torigoe et al18 This mouse mAb is commercially available (Hokudo) 
and reacts with the extracellular domains of HLA-A*2402, A*0101, 
TA B L E  1   Characteristics of patients and oral squamous cell 
carcinoma tumors

















N (−) 108 78.8
N (+) 29 21.2
Stage grouping
Stage I 42 30.7
Stage II 61 44.5
Stage III/IV 34 24.8
Histopathological grading
Grade 1 73 53.3
Grade 2 59 43.1
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A*1101, A*0201, A*0207, B*0702, B*0801, B*1501, B*3501, 
B*4001, B*4002, B*4006, B*4403, Cw*0102, Cw*0801, Cw*1202, 
and Cw*1502.22 Immunohistochemical staining with EMR8-5 was 
carried out on formalin-fixed, paraffin-embedded tissue sections 
after steam heat-induced epitope retrieval. Subsequent incubations 
with a secondary biotinylated Ab, avidin-conjugated peroxidase 
complex, and chromogen were undertaken on a Ventana NexES sys-
tem (Ventana Medical Systems).23 The slides were counterstained 
with hematoxylin, rinsed, dehydrated in a graded ethanol series, and 
coverslipped with mounting media. Positive reactivity to EMR8-5 
was confirmed by staining vascular endothelial cells and lympho-
cytes in sections of tumor specimens.22 In addition, tissue sections 
were incubated with a primary mAb against pan-cytokeratin (1:200, 
clone AE1/AE3; Abcam) to detect multiple cytokeratins and identify 




The histological slides were evaluated for lymphovascular invasion, 
perineural invasion, and histopathological grading. Tumor extent 
and histopathological grading were classified according to the can-
cer staging manual of the American Joint Committee on Cancer.24 
Human leukocyte antigen class Ⅰ expression was evaluated at the 
TCe and IF at ×200 magnification (Figure 1). For the assessment of 
HLA class Ⅰ density in each compartment (ie, TCe and IF), at least 
5 fields were viewed, and in heterogeneous cases, the most repre-
sentative area of the entire section was selected. The HLA class Ⅰ 
expression was assessed on a personal computer with DP2-BSW 
software and an Olympus microscope digital camera by three indi-
viduals (authors KK, SS, and HD) (Figure 2). Labels bearing the pa-
tient pathology number were covered. Human leukocyte antigen 
class Ⅰ expression was classified into 3 categories as previously de-
scribed25: high (more than 50% positive cells), low (5%-50% positive 
cells), and negative (less than 5% positive cells). Briefly, positivity was 
defined as complete and homogeneous membrane staining in more 
than 50% of tumor cells; low positive expression was defined as 
faint, incomplete, and heterogeneous membrane staining in 5%-50% 
of tumor cells; and negative expression was defined as membrane 
staining in less than 5% of tumor cells. CD8+ T cell expression was 
also evaluated at the TCe and IF at ×200 magnification (Figure 3). 
The mean CD8+ T cell density for each compartment was used to 
stratify the samples into the high- and low-density groups according 
to our previous report.19
2.4 | Statistical analysis
Disease-specific survival was calculated from the date of definitive 
surgery to date of death. Overall survival was defined as the time 
between the date of definitive surgery and date of death from any 
cause. Recurrence-free survival was defined as the time between 
the date of definitive surgery and locoregional or distant tumor re-
currence, or death from any cause. Disease-specific survival, OS, and 
RFS were analyzed using the Kaplan-Meier method and compared 
using a log-rank test for each group. Variables that had prognostic 
potential indicated by univariate analysis were evaluated using mul-
tivariate analysis with Cox proportional hazard regression models. 
Associations between HLA class I expression and CD8+ T cell infil-
tration density were evaluated using a χ2 test. Two-tailed P-values 
less than 0.05 were considered statistically significant. SPSS version 
23.0 for Windows (IBM) was used for statistical analyses.
3  | RESULTS
3.1 | Patient and tumor characteristics
From January 2004 to December 2014, a total of 221 patients with 
primary OSCC were treated by curative surgery. Of these, 137 pa-
tients were treated without neoadjuvant or adjuvant therapy, and 
sufficient tissue samples from these patients were available for 
further analysis. The 137 patients with OSCC comprised 76 men 
(55.5%) and 61 women (44.5%) with a median age of 68 (range, 33-
93) years at first presentation. Anatomical sites included the tongue/
floor of the mouth (89 tumors, 65.0%) and other regions of the oral 
cavity (48 tumors, 35.0%). Using the UICC staging classification 
system, the participants were classified as follows: 42 patients in 
F I G U R E  1   Representative H&E 
staining and immunohistochemical pan-
cytokeratin labeling of oral squamous cell 
carcinoma sections for the assessment of 
2 distinct tumor compartments. Tumor 
center (TCe) and invasive front (IF) were 
evaluated. Pan-cytokeratin expression 
was detected using a primary mAb (clone 
AE1/AE3; Abcam)
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stage I (30.7%), 61 in stage Ⅱ (44.5%), and 34 in stage Ⅲ/Ⅳ (24.8%). 
Histopathological grading was as follows: 73 patients were assigned 
grade 1 (53.3%), 59 were assigned grade 2 (43.1%), and 5 were as-
signed grade 3 (3.6%). One hundred and fifteen patients (83.9%) did 
not have lymphovascular invasion, whereas it was present in 22 pa-
tients (16.1%); 125 patients (91.2%) did not have perineural invasion, 
but it was present in 12 patients (8.8%).
3.2 | Relationship between clinicopathological 
data and survival rates
The median follow-up period for all patients was 79 (range, 4-164) 
months. Primary tumors recurred in 16 patients (11.6%), and regional 
lymph node relapse was observed in 24 patients (17.5%). Five-year 
DSS, OS, and RFS rates for all patients were 90.5%, 83.2%, and 
62.8%, respectively (Table 2). Age and perineural invasion were 
associated with DSS, OS, and RFS and thus considered important 
indicators.
4  | E xpression of  HL A class Ⅰ  in  OSCC 
sec t ions
Expression of HLA class I was measured in the OSCC sections to 
evaluate different tumor regions. At the IF, 72 cases (52.6%) had 
high HLA class I expression, 44 (32.1%) had low expression, and 
21 (15.3%) were negative. At the TCe, 48 cases (35.0%) had high 
HLA class I expression, 58 (42.4%) had low expression, and 31 
(22.6%) were negative. These results indicated that HLA class I 
molecules are expressed differentially in different compartments 
of OSCC.
5  | Relat ionship bet ween HL A class Ⅰ 
expression and sur viva l  rates
Patients with high HLA class I expression at the IF had significantly 
better OS than those with low or negative expression (90.3%, 79.5%, 
and 66.7%, respectively, P = 0.03). In contrast, there was no signifi-
cant difference in survival based on HLA class I expression in the 
TCe (Figure 4). Disease-specific survival was better in patients with 
F I G U R E  2   Immunohistochemical 
labeling of oral squamous cell carcinoma 
sections for the assessment of human 
leukocyte antigen (HLA) class I expression. 
HLA class I expression was classified into 
3 categories: high (>50% positive cells), 
low (5%-50% positive cells), and negative 
(<5% positive cells). To detect tumor 
cells, immunohistochemistry was carried 
out using a primary mAb against pan-
cytokeratin (clone AE1/AE3; Abcam)
F I G U R E  3   Representative 
immunohistochemical CD8⁺ T cell and 
human leukocyte antigen (HLA) class I 
density of oral squamous cell carcinoma 
sections for the assessment of 2 distinct 
tumor compartments. Tumor center (TCe) 
and invasive front (IF) were evaluated
     |  1495KOIKE Et al.
high HLA class I expression at the IF compared with patients with 
low and negative expression (P = 0.04), whereas there was no signifi-
cant difference in DSS according to HLA class I expression in the TCe 
(Figure 5). Recurrence-free survival was not significantly different 
among all patients (Figure 6). Together, these results indicated that 
HLA class I expression at the IF could be a prognostic factor for OS 
and DSS in patients with OSCC.
In multivariate analysis, HLA class I expression at the IF was 
an independent prognostic factor for OS (hazard ratio 0.43; 95% 
confidence interval, 0.20-0.91; P = 0.02). Age, stage grouping, and 
perineural invasion were independent prognostic factors for OS 
and DSS. Moreover, none of the parameters were independent 
prognostic factors for RFS. Overall, these results suggested that 
HLA class I expression at the IF could be a prognostic factor for OS 
(Table 3).
6  | Relat ionship bet ween HL A class Ⅰ 
expression and CD8+ T  ce l l  densit y
At the IF, high HLA class I expression was correlated with high CD8⁺ T cell 
density. In addition, negative HLA class I expression was correlated with 
low CD8⁺ T cell density. In contrast, there was no significant difference in 
the TCe (Table 4). These results suggested that it is easier for CD8⁺ T cells 
TA B L E  2   Five-year overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) according to 





(P value) Survival rate (%)
Log-rank test 




Male 82.9 0.930 90.8 0.890 65.8 0.340
Female 83.6  90.2  59.0  
Age, y
<68 95.2 0.001 98.4 0.003 74.6 0.010
≥68 73.0  83.8  52.7  
Anatomical site
Tongue/floor of the 
mouth
88.8 0.009 94.4 0.020 66.3 0.160
Other 72.9  83.3  56.3  
Primary tumor
T1 95.7 0.001 97.8 0.030 69.6 0.120
T2 80.5  88.3  62.3  
T3/4 57.1  78.6  42.9  
Regional lymph nodes
N (−) 88.0 0.001 95.4 <0.001 65.7 0.170
N (+) 65.5  72.4  51.7  
Stage grouping
Stage I 97.6 <0.001 100.0 0.001 71.4 0.140
Stage II 83.6  91.8  63.9  
Stage III/IV 64.7  76.5  50.0  
Histopathological grading
Grade 1 87.7 0.330 94.5 0.210 71.2 0.003
Grade 2 78.0  86.4  55.9  
Grade 3 80.0  80.0  20.0  
Lymphovascular invasion
Absent 86.1 0.050 92.2 0.140 67.0 0.010
Present 68.2  81.8  40.9  
Perineural invasion
Absent 86.4 <0.001 92.8 0.001 66.4 0.001
Present 50.0  66.7  25.0  
Two-tailed P-values less than 0.05 were considered statistically significant.
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to recognize presented peptides in the case of high HLA class I expres-
sion at the IF, whereas the ability of CD8⁺ T cells to recognize presented 
peptides in the case of low HLA class I expression is impaired.
7  | DISCUSSION
There are several clinical and pathological prognostic factors for can-
cer, but only a few immunological prognostic methods. The immuno-
logical state of the host can influence the prognosis and features 
of cancer. Human leukocyte antigen class I molecules play a central 
role in cell-mediated immunity, especially as antigen-presenting mol-
ecules for CTLs, which recognize tumor antigen-bound peptides pre-
sented on the cell surface through HLA class I molecules and kill the 
target cancer cell.26,27 Human leukocyte antigen class I expression 
appears to be lost or downregulated on the tumor cell surface, which 
could represent a mechanism for neoplastic cells to escape killing 
by CTLs, allowing tumor dissemination and metastasis.28 The total 
loss of HLA class I expression reportedly occurs in approximately 
15% and 40% of primary and metastatic head and neck SCC lesions, 
F I G U R E  4   Relationship between human leukocyte antigen (HLA) class I expression and 5-year overall survival (OS) of patients with oral 
squamous cell carcinoma. The orange line indicates high HLA class I expression, the green line indicates low HLA class I expression, and the 
blue line indicates negative HLA class I expression. Patients with high HLA class I expression at the invasive front (IF) showed better OS than 
those with low or negative expression. However, there was no difference in OS based on HLA class I expression in the tumor center (TCe)
F I G U R E  5   Relationship between human leukocyte antigen (HLA) class I expression and 5-year disease-specific survival (DSS) of patients 
with oral squamous cell carcinoma. The orange line indicates high HLA class I expression, the green line indicates low HLA class I expression, 
and the blue line indicates negative HLA class I expression. Patients with high HLA class I expression at the invasive front (IF) had a better 
DSS rate than those with low and negative expression. In contrast, there was no difference in DSS based on HLA class I expression in the 
tumor center (TCe)
F I G U R E  6   Relationship between human leukocyte antigen (HLA) class Ⅰ expression and 5-year recurrence-free survival (RFS) of patients 
with oral squamous cell carcinoma. The orange line indicates high HLA class Ⅰ expression, the green line indicates low HLA class Ⅰ expression, 
and the blue line indicates negative HLA class Ⅰ expression. There was no difference in RFS according to HLA class Ⅰ expression (high, low, or 
negative) in each tumor region
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respectively.29 Similarly, in our study, the loss of HLA class I expres-
sion at the IF was observed in 15% (21/137) of cases.
Recent reports have shed light on the immunological tumor 
microenvironment and immune escape mechanisms of cancer 
cells,30-35 but a detailed understanding is still lacking. The clinical 
relevance of the immunological tumor microenvironment, including 
the prognostic value of CD8⁺ T cells, is controversial and remains to 
be elucidated.30-31,36,37 In addition, the prognostic value of the spa-
tial heterogeneity (IF vs TCe) of tumor-infiltrating lymphocytes and 
immune escape mechanisms remains unclear.
Therefore, we focused on the expression of HLA class I mole-
cules to identify possible novel immunological prognostic factors. 
Our data showed that high HLA class I expression at the IF of OSCC 
was significantly related to better OS and DSS compared with low 
or negative HLA class I expression, which was consistent with the 
findings of other studies7,21 and suggests that the level of HLA class I 
expression at the IF could be a prognostic factor. Because HLA class 
I expression at the IF was associated with decreased cancer cell pro-
liferation and metastasis based on survival, it might exert a protec-
tive effect against cancer. In addition, we previously reported that 
CD8⁺ T cell density at the IF was an indicator of tumor recurrence 
and prognosis.19 The cases analyzed in our previous and present 
studies largely overlapped, but in the present study, we analyzed the 
relationship between CD8⁺ T cell density and HLA class I expres-
sion. Negative HLA class I expression was correlated with low levels 
of CD8⁺ T cells at the IF, but there was no significant difference in 
the TCe. It is possible that CD8⁺ T cells were concentrated at the 
IF because tumor vasculature was enriched in the infiltrative mar-
gin, but not in the tumor center. In addition, we found that CD8⁺ T 
cells were not recruited to sites where HLA class I expression was 
downregulated.
Tsukahara et al reported that patients with osteosarcoma who 
had high HLA class I expression had significantly better OS and dis-
ease-free survival than those with HLA class I-negative osteosar-
coma.22 Most reports, including the present study, suggest that the 
downregulation of HLA class I expression is associated with poor 
prognosis. In contrast, Madjd et al reported that the total loss of 
HLA class I expression was an independent indicator of good prog-
nosis in breast cancer.38 They considered that the loss of HLA class I 
TA B L E  3   Multivariate analysis of overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) in patients with 
oral squamous cell carcinoma
Parameters
OS DSS RFS
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Immunohistochemical findings
TCe 0.56 0.26-1.18 0.13 0.13 0.01-1.02 0.05 0.81 0.50-1.31 0.40
IF 0.43 0.20-0.91 0.02 0.38 0.11-1.26 0.11 0.80 0.52-1.24 0.32
Clinical findings
Sex 0.53 0.21-1.31 0.17 0.64 0.17-2.28 0.48 1.17 0.66-2.07 0.59
Age 5.13 1.35-19.37 0.01 28.00 1.48-529.22 0.02 1.74 0.89-3.42 0.10
Anatomical site 1.92 0.64-5.74 0.24 1.49 0.25-8.89 0.65 1.18 0.58-2.38 0.63
Primary tumor 1.63 0.64-4.16 0.30 1.49 0.37-3.87 0.76 1.11 0.54-2.30 0.76




1.08 0.49-2.34 0.84 1.31 0.40-4.21 0.64 1.53 0.90-2.59 0.11
Lymphovascular invasion 2.49 0.92-6.69 0.07 3.77 0.68-14.82 0.13 1.62 0.82-3.20 0.16
Perineural invasion 3.58 1.15-11.13 0.02 6.85 1.12-41.75 0.03 2.02 0.87-4.68 0.09
Two-tailed P-values less than 0.05 were considered statistically significant.
Abbreviations: CI, confidence interval; HR, hazard ratio; IF, invasive front; TCe, tumor center.
TA B L E  4   Relationship between human leukocyte antigen (HLA) 
class I expression and infiltrating CD8+ T cell density in patients 
with oral squamous cell carcinoma
 
Number of cases with CD8+ T cell 
density
Low, n (%) High, n (%) P value
HLA class I expression
IF
Negative (n = 21) 17 (81.0) 4 (19.0) 0.003
Low (n = 44) 31 (70.5) 13 (29.5)  
High (n = 72) 33 (45.8) 39 (54.2)  
TCe
Negative (n = 31) 23 (74.2) 8 (25.8) 0.050
Low (n = 58) 28 (48.3) 30 (51.7)  
High (n = 48) 25 (52.1) 23 (47.9)  
Two-tailed P-values less than 0.05 were considered statistically 
significant.
Abbreviations: IF, invasive front; TCe, tumor center.
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molecules could make tumors more susceptible to NK cells and result 
in a better prognostic outcome due to the presence of HLA class I al-
lele-specific killer cell inhibitory receptors on the surface of NK cells. 
Thus, in the absence of HLA class I expression, specific killer cell 
inhibitory receptor-mediated inhibitory signaling is lost and NK cy-
tolytic effector functions are activated. Natural killer cell-mediated 
cytotoxicity is regulated by a delicate balance between activating 
and inhibitory signals. Therefore, the prognostic influence of HLA 
class I expression might depend on the status of cancer immunity.
We observed a few cases in which HLA class I expression and 
CD8⁺ T cell density were not correlated, but this could be explained 
by the presence of IFN-γ, which is a central cytokine that coordi-
nates tumor immune responses and the associated biological con-
sequences.39,40 In fact, detection of IFN-γ mRNA expression at the 
IF has been reported in tumor cells and immune cells in OSCC.7 In 
the present study, we confirmed CD4⁺ T cell infiltration at the IF 
(Figure S1). Because IFN-γ is secreted mainly by activated CD4⁺ T 
cells, we considered that this IFN-γ might be responsible for the up-
regulation of HLA class I molecules.
Many studies on HLA class I expression in cancer have pro-
duced contradictory results, perhaps due to the use of highly 
heterogeneous populations and because the distribution of HLA 
alleles and the linkage disequilibrium among alleles of diverse 
HLA genes differ in various ethnic populations.41 In addition, rel-
atively small populations were included in several studies, and 
the Abs, immunostaining methods, and scoring systems differed. 
Finally, the cut-off used to classify downregulation and HLA class 
I-positive groups varied substantially. Due to the differences in 
these criteria, a reliable comparison of these studies is difficult to 
carry out.
Our study showed a survival benefit for patients expressing HLA 
class I molecules, suggesting that the class I-restricted CTL pathway 
plays a major role in immune surveillance in patients with OSCC. Due 
to the small sample size of the present analysis, larger studies need 
to be undertaken to verify the significance of HLA class I expression 
in prognosis and the applicability of T cell-based immunotherapy for 
patients with OSCC.
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